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Summary. C-reactive protein (CRP) has been proposed as a
risk factor for cardiovascular disease; however, this associ-
ation is confounded by mutual relationships with both
classical and haematological cardiovascular risk factors.
We, therefore, measured CRP with a high-sensitivity assay
in stored plasma samples from 414 men and 515 women in
the north Glasgow MONICA (MONItoring trends in CArdio-
vascular diseases) survey, to study its correlation with
haematological variables, classical risk factors and prevalent
cardiovascular disease. CRP correlated with age, oral con-
traceptive use, menopause and most classical cardiovascu-
lar risk factors (except blood pressure). CRP also correlated
with plasma levels of the pro-inflammatory cytokine inter-
leukin 6, and haematocrit, viscosity, red cell aggregation,
white cell count, and coagulation factors [fibrinogen, factor
(F) VII in women, FVIII, FIX] and inhibitors (antithrombin
and protein C in women; protein S) but not coagulation
activation markers. CRP was significantly associated with
prevalent cardiovascular disease in both men (P ¼ 0Æ03)
and women (P ¼ 0Æ009), however, the association became
non-significant after adjustment for firstly classical risk
factors, then fibrinogen. We conclude that correlations with
classical and haematological risk factors account for a
substantial component of the association of CRP with pre-
valent cardiovascular disease, but there is evidence of a
residual, independent effect among women.
Keywords: C-reactive protein, thrombosis, cardiovascular
disease, fibrinogen, inflammation.
There is increasing interest in the plasma or serum level of
C-reactive protein (CRP), a commonly assayed marker of
the reactant plasma protein component of the inflamma-
tory response, as a predictor of cardiovascular disease
(CVD), including coronary heart disease (CHD) (Danesh
et al, 2000a), stroke (Ford & Giles, 2000; Gussekloo et al,
2000), peripheral arterial disease (Ridker et al, 1998) and
venous thromboembolism (Lowe et al, 2000). While it has
been suggested that CRP is an ‘independent’ risk factor for
CHD and may play a causal role in CHD (Lagrand et al,
1999), the association of CRP with CVD may partly reflect
mutual associations with established CVD risk factors
(Danesh et al, 2000a). CRP is also associated with haema-
tological risk predictors of CVD, including fibrinogen, plasma
viscosity and white cell count, which (like CRP) are
associated with acute-phase reactions mediated by cytokines
such as interleukin 6 (IL-6) (Woodward et al, 1999; Danesh
et al, 2000b; Mendall et al, 2000; Lowe et al, 2001).
We, therefore, assayed plasma CRP levels using a high-
sensitivity automated immunonephelometric assay (Lowe
et al, 2001), and related them to established CVD risk
factors, haematological CVD risk factors, plasma IL-6 and
prevalent CVD in a random UK population sample: the third
North Glasgow MONICA (MONItoring trends in CArdiovas-
cular diseases) survey (Lowe et al, 1997, 1999; Woodward
et al, 1997, 1999).
SUBJECTS AND METHODS
Between January and August 1992, 1958 men and
women, aged 25–74 years, were randomly sampled from
the area of Glasgow which lies north of the River Clyde, as
the third in a series of samples from this population contri-
buting to the international MONICA Project (World Health
Organization Principal Investigators, 1988). Subjects were
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sent, by post, a questionnaire to bring with them for
checking at a screening clinic. Included in this question-
naire were the Rose chest pain and Edinburgh claudication
questionnaires, and questions on socio-demographic status,
past medical history, smoking and alcohol consumption,
and female contraceptive and hormone replacement ther-
apy use, menopause and pregnancy. At the clinic, height,
weight, blood pressure, a 12-lead electrocardiogram and
carbon monoxide (CO) in expired air were recorded, and a
non-fasting blood sample was taken by trained nurses,
centrifuged, and plasma and serum aliquots stored at
)70C. Clinic sessions took place between 09.00 hours
and 16.00 hours (Lowe et al, 1997; Woodward et al,
1997).
From the blood samples, total and high-density lipopro-
tein (HDL) cholesterol, triglycerides, thiocyanate and coti-
nine were measured in serum, and vitamin C was measured
in plasma (Woodward et al, 1997). Details of statistical
sampling procedures (Crombie et al, 1989), assays of lipids
(Smith et al, 1989), objective measures of tobacco smoke
inhalation [carbon monoxide in expired air (CO), thiocya-
nate (SCN) and cotinine] (Woodward et al, 1991), and
vitamin C levels (Vuilleumier & Keck, 1989)1 have been
reported previously. Haematological variables measured
included coagulation factors, inhibitors and markers:
fibrinogen, factor (F)VII, FVIII, FIX, antithrombin, protein
C, protein S, prothrombin fragment 1 + 2 (F1 + 2), and
thrombin–antithrombin (TAT) complexes (Lowe et al,
1997); whole blood viscosity, haematocrit, plasma viscosity,
relative blood viscosity, red cell aggregation, white cell
count and IL-6 (Woodward et al, 1999); and activated
protein C (APC) ratio and activated partial thromboplastin
time (APTT) (Lowe et al, 1999). CRP was measured in
residual plasma samples using a high-sensitivity immuno-
nephelometric assay (Dade Behring, Marburg, Germany;
Lowe et al, 2001).
Statistical methods. Subjects were classified as having
prevalent CVD if: they self-reported a prior doctor diagnosis
of angina, myocardial infarction or stroke; they reported the
correct sequence of answers to either the Rose or Edinburgh
claudication questionnaires; or they exhibited Q/QS or ST or
T wave changes on their electrocardiogram, as previously
described (Woodward et al, 1997).
As the distribution of CRP was highly skewed, it was
summarized using percentiles: the three quartiles and the
5th)95th percentile range. For the same reason, Spear-
man’s rank correlation coefficients were used to summarize
associations. A log transformation was used to improve the
approximation of a normal probability distribution before
any statistical tests were carried out or confidence limits
calculated.
CRP was compared with thrombotic variables, commonly
accepted cardiovascular risk factors (including smoking and
drinking) and social class. Cigarette status was classified
according to self-report as never/ex/current, and CO, SCN
and cotinine were all used as objective biochemical meas-
ures of smoking to assess current smoking dose. Alcohol
was recorded as consumption in the past, and in the week
prior to completing the questionnaire. The data were
categorized into never/zero (no consumption in the past
week)/low/medium/high, where the class limits for the last
three groups are the sex-specific tertiles of last week’s
consumption. Social class was classified as manual/non-
manual according to occupation (Office of Population
Censuses and Surveys, 1990), with married women coded
according to their husband’s occupation.
Odds ratios (OR) for prevalent CVD, by equal quarters of
CRP, were estimated from logistic regression models. Tests
for log linearity were carried out using the rank of each
quarter as a continuous measure in the logistic regression
model. Correlations and OR were adjusted for age, as age is
a fundamental determinant of most of the variables consid-
ered. OR for CRP were also calculated after further
adjustment for a range of cardiovascular risk factors that
might be considered potential confounders.
RESULTS
CRP was measured in 414 men and 550 women, this being
49% of the entire study population. There was insufficient
remaining plasma to measure CRP in the remaining 51%.
Table I shows CRP levels, in men and women, by 10-year
age groups. CRP rose with age (P < 0Æ0001) in each sex
group, but was not significantly different between the sexes
(P ¼ 0Æ47). Note that the lower limit of 0Æ18 mg/l in many
age/sex groups was the lowest level that the assay could
measure. Current oral contraceptive use was significantly
(P ¼ 0Æ02) associated with a higher level of CRP in non-
pregnant, premenopausal women aged 25–34 years. Med-
ian (fifth percentile, first quartile, third quartile, 95%
Table I. Age and sex-specific distributions for CRP (mg/l).
n
Age (years)
25–34 35–44 45–54 55–64 65–74
Men 414 0Æ47 (0Æ19, 1Æ08) 0Æ86 (0Æ33, 1Æ71) 1Æ12 (0Æ51, 1Æ86) 2Æ13 (0Æ91, 4Æ40) 1Æ42 (0Æ70, 3Æ04)
0Æ18–2Æ53 0Æ18–8Æ73 0Æ19–7Æ28 0Æ30–10Æ00 0Æ34–8Æ93
Women 550 0Æ68 (0Æ26, 2Æ10) 0Æ67 (0Æ34, 1Æ42) 1Æ08 (0Æ48, 2Æ18) 1Æ15 (0Æ65, 2Æ38) 1Æ46 (0Æ70, 4Æ45)
0Æ18–6Æ85 0Æ18–6Æ16 0Æ18–6Æ63 0Æ18–9Æ47 0Æ19–12Æ90
Summary statistics shown are median (first, third quartile) and 5th percentile to 95th percentile.
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percentile) values were 1Æ11 (0Æ18, 0Æ41, 3Æ65, 7Æ05) for
those who used oral contraceptives (n ¼ 36) and 0Æ46
(0Æ18, 0Æ26, 1Æ47, 3Æ81) for those who did not (n ¼ 53).
Among the non-pregnant 45–54-year-old women not
taking hormone replacement therapy, postmenopausal
women had significantly (P ¼ 0Æ05) higher values of CRP
than premenopausal women. Medians (and values as
above) were 1Æ32 (0Æ18, 0Æ62, 2Æ44, 7Æ27) for postmeno-
pausal women (n ¼ 45) and 0Æ63 (0Æ18, 0Æ29, 1Æ23, 2Æ83)
for premenopausal women (n ¼ 42). Among all non-
pregnant women aged 45–54 years, those taking hormone
replacement therapy (n ¼ 26) had higher CRP levels than
other postmenopausal women. This difference was not
significantly different (P ¼ 0Æ55), but the lack of signifi-
cance could be as a result of the small numbers involved:
the median (and values as above) CRP for hormone
replacement therapy users was 2Æ15 (0Æ25, 0Æ71, 2Æ93,
8Æ97).
CRP was significantly related to most of the haematolog-
ical variables assayed, as well as IL-6 (Table II). Even taking
an extreme significance level (to protect against multiple
significance testing) of 0Æ1%, CRP was significantly linearly
associated with: fibrinogen, FIX, protein S, plasma viscosity
and white cell count in both sexes; FVIII and IL-6 in men;
and FVII, antithrombin, protein C, corrected blood viscosity,
red cell aggregation and whole blood viscosity in women.
Indeed, the only variables in Table II for which there was
definitely no indication (P > 0Æ05) of a linear association
with CRP were F1 + 2 (both assays), TAT and relative
blood viscosity. All the relationships with CRP were in the
positive direction except for APTT (men) and APC ratio
(women). In most cases, the associations with CRP were
similar in each sex group: exceptions were FVII, antithrom-
bin and protein C, which were much stronger in women.
Table III shows relationships between CRP and continu-
ous cardiovascular risk factors. Taking the 0Æ1% level of
significance once more, CRP was significantly positively
monotonically associated with: body mass index [weight/
(height squared)] in both sexes; serum thiocyanate and
cotinine in men; and serum total cholesterol and triglycer-
ides in women. It was significantly negatively associated
with serum HDL cholesterol in women. As in Table II, it is
easier to list the variables for which there is definitely no
evidence of association: here only blood pressure showed no
such evidence (P > 0Æ05). The apparent sex difference in the
association of CRP with total cholesterol (only of importance
in women) is of note.
Categorical risk factors are the subject of Table IV. In
agreement with the results for CO, SCN and cotinine in
Table III, current smoking appeared to elevate CRP. How-
ever, there was no evidence that ex-smokers had different
CRP levels to those who had never smoked, nor of any
effects of alcohol on CRP. Women of relatively high social
class had a significantly (P ¼ 0Æ0008) higher CRP than
other women, but social class appeared to have no such role
for men (P ¼ 0Æ60).
Of the men, 123 (30%) had prevalent CVD; of the
women, 174 (32%) had prevalent CVD. Of those with CVD,
Table II. Age-adjusted Spearman’s rank correlations between CRP and coagulation
factor activities, inhibitor activities, activation markers and rheological variables.
Men Women
r P-value* r P-value*
Fibrinogen 0Æ36 0Æ0001 0Æ39 0Æ0001
FVII 0Æ07 0Æ19 0Æ25 0Æ0001
FVIII 0Æ17 0Æ0005 0Æ12 0Æ005
FIX 0Æ23 0Æ0001 0Æ40 0Æ0001
Antithrombin )0Æ006 0Æ91 0Æ19 0Æ0001
Protein C 0Æ01 0Æ81 0Æ14 0Æ001
Protein S 0Æ19 0Æ0004 0Æ18 0Æ0002
F1 + 2 (London) )0Æ02 0Æ76 0Æ07 0Æ29
F1 + 2 )0Æ03 0Æ59 0Æ03 0Æ52
TAT 0Æ08 0Æ14 )0Æ05 0Æ28
APTT )0Æ13 0Æ04 )0Æ06 0Æ29
APC ratio 0Æ03 0Æ61 )0Æ11 0Æ04
Whole blood viscosity 0Æ17 0Æ002 0Æ22 0Æ0001
Haematocrit 0Æ13 0Æ02 0Æ11 0Æ02
Corrected blood viscosity 0Æ16 0Æ005 0Æ22 0Æ0001
Plasma viscosity 0Æ38 0Æ0001 0Æ28 0Æ0001
Relative blood viscosity )0Æ007 0Æ91 0Æ04 0Æ43
Red cell aggregation 0Æ17 0Æ003 0Æ28 0Æ0001
White cell count 0Æ30 0Æ0001 0Æ22 0Æ0001
IL-6 0Æ28 0Æ001 0Æ22 0Æ003
*P-value of 0Æ0001 means P £ 0Æ0001.
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the vast majority (93%) had CHD; the remainder had
cerebrovascular or peripheral vascular disease. CRP was
significantly linearly related to prevalent CVD, such that the
odds of having the disease generally increased (P < 0Æ05)
with increasing CRP across its quarters (Table V), for both
men and women, after adjustment for age. After further
adjustment for major cardiovascular risk factors, the OR
decreased appreciably. The trend was then no longer
statistically significant, although there was still a clear
indication of a rise in odds with increasing CRP (Table V).
Even after the multiple adjustment, women in the highest
quarter (2Æ38 mg/l or greater) had significantly higher odds
of prevalent CVD than those in the lowest quarter (below
0Æ41 mg/l), the estimated OR being 1Æ87. Further adjust-
ment for fibrinogen abolished any trend for association of
CRP with CVD in men, but had no effect on this association
in women (Table V).
DISCUSSION
While there is current interest in the potential role of CRP
as a predictor of CVD, there is controversy as to its direct
role. A causal role for CRP has been postulated (Lagrand
et al, 1999). While CRP appears to be an ‘independent’
risk factor for CHD in meta-analyses of prospective studies,
this association is substantially reduced on adjustment
for established CHD risk factors, which correlate with CRP
levels (Danesh et al, 1999). CRP is also associated with
several acute-phase reactant haematological CHD risk
factors, including fibrinogen, white cell count and plasma
Table III. Age-adjusted Spearman’s rank correlations between CRP and cardio-
vascular risk factors that are continuous variables.
Men Women
r P-value* r P-value*
Total cholesterol 0Æ06 0Æ20 0Æ17 0Æ0001
HDL cholesterol )0Æ14 0Æ007 )0Æ21 0Æ0001
Triglycerides 0Æ11 0Æ02 0Æ34 0Æ0001
Diastolic blood pressure 0Æ07 0Æ16 0Æ07 0Æ12
Systolic blood pressure 0Æ03 0Æ57 0Æ05 0Æ21
Body mass index 0Æ19 0Æ0001 0Æ31 0Æ0001
Plasma vitamin C )0Æ11 0Æ03 0Æ14 0Æ002
Carbon monoxide 0Æ11 0Æ03 0Æ10 0Æ02
Thiocyanate 0Æ17 0Æ0007 0Æ12 0Æ004
Cotinine 0Æ16 0Æ001 0Æ12 0Æ005
*P-value of 0Æ0001 means P £ 0Æ0001.
Table IV. Age-adjusted mean CRP (mg/l) by drinking habit, smoking habit and social class.
Men Women
Mean (95% CI) P-value Mean (95% CI) P-value
Alcohol intake 0Æ56 0Æ46
Never 0Æ86 (0Æ54–1Æ32) 0Æ88 (0Æ66–1Æ18)
Zero* 1Æ25 (0Æ98–1Æ61) 1Æ18 (0Æ98–1Æ41)
Low 1Æ07 (0Æ86–1Æ35) 1Æ03 (0Æ80–1Æ33)
Medium 1Æ01 (0Æ81–1Æ26) 0Æ96 (0Æ76–1Æ22)
High 1Æ03 (0Æ84–1Æ26) 1Æ09 (0Æ86–1Æ39)
Cigarette smoker
Never 0Æ93 (0Æ73–1Æ19) 0Æ04 0Æ86 (0Æ73–1Æ02) 0Æ003
Ex 1Æ02 (0Æ83–1Æ25) 1Æ13 (0Æ91–1Æ41)
Current 1Æ26 (1Æ08–1Æ46) 0Æ57 1Æ24 (1Æ05–1Æ45) 0Æ05
Social class 0Æ60 0Æ0008
Non-manual 1Æ17 (0Æ93–1Æ48) 0Æ85 (0Æ72–1Æ00)
Manual 1Æ09 (0Æ97–1Æ24) 1Æ22 (1Æ07–1Æ39)
*Zero in past week, but currently a drinker.
95% CI, 95% confidence interval.
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viscosity (Danesh et al, 2000a,b; Mendall et al, 2000). In
the Caerphilly Prospective Heart Disease Study in men,
Mendall et al (2000) observed that the association of CRP
with incident CHD was abolished after adjustment for
established CHD risk factors and fibrinogen.
There are few published studies on the associations of
CRP with established cardiovascular risk factors in healthy
persons (Danesh et al, 1999; Hak et al, 1999; Yudkin et al,
1999; Mendall et al, 2000). Only one of these studies also
included haematological predictors of CHD (Mendall et al,
2000), which were limited to fibrinogen, white cell and
platelet counts, and plasma viscosity. Also, this study was
restricted to men. In the third north Glasgow MONICA
survey, which had approximately equal numbers of men
and women, we have performed an extensive profile of
established and haematological cardiovascular risk factors
(including coagulation times, factors, inhibitors and activa-
tion markers) rheological variables, white cell count and the
pro-inflammatory cytokine IL-6 (Lowe et al, 1997, 1999;
Woodward et al, 1997, 1999). This has enabled us to
perform a detailed analysis of the relationships of CRP with
all these risk factors, as well as to prevalent CVD.
We confirmed a recent report of an increase in CRP with
age (Hutchison et al, 2000). While we observed no signi-
ficant difference in CRP levels between men and women, we
confirmed previous reports that current usage of oral
contraceptives (Fro¨hlich et al, 1999)2 or of oral hormone
replacement therapy (Cushman et al, 1999; Ridker et al,
1999; Lowe et al, 2000) was associated with elevated CRP
levels. The distribution of CRP in Glasgow is similar to that
in representative populations of Germany and France
(Imhof et al, 2003).
CRP levels correlated significantly with levels of the pro-
inflammatory cytokine IL-6, in accordance with the report
of Yudkin et al (1999). CRP levels also correlated signifi-
cantly with other haematological measures of the acute-
phase response, including fibrinogen, white cell count and
plasma viscosity. These findings are similar to those of
Mendall et al (2000) in men, and confirm similar associa-
tions in women. Furthermore, we observed significant
correlations of CRP with other rheological measures (blood
viscosity, haematocrit, red cell aggregation) and coagula-
tion factors (factors VII, VIII and IX, especially in women)
that are associated with cardiovascular risk. However, we
observed no association of CRP with coagulation activation
markers, possibly because CRP was also associated with
coagulation inhibitors, especially in women (Table II).
We confirmed that CRP correlated with most established
cardiovascular risk factors, except blood pressure (Tables III
and IV). These findings are generally consistent with those
of other recent reports (Danesh et al, 1999; Hak et al, 1999;
Yudkin et al, 1999; Mendall et al, 2000). Two of these
reports highlighted the association of CRP with measures of
insulin resistance, including tissue plasminogen activator
antigen (Hak et al, 19993 ; Yudkin et al, 1999). We observed
no association of CRP with alcohol consumption, and an
inverse association with social class only in women.
We observed an association of CRP with prevalent CVD
on univariate analysis in both men and women, which wasT
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reduced to non-statistical significance by adjustment for
established cardiovascular risk factors (Table V). Further
adjustment for fibrinogen abolished any trend for associ-
ation of CRP with CVD in men, as observed by Mendall et al
(2000) in the prospective Caerphilly study, but had no effect
on this association in women. The reason for this sex
difference is unclear and requires gender comparisons in
large prospective studies.
In conclusion, we have confirmed: (a) that CRP is
significantly associated with most established, and haema-
tological, cardiovascular risk factors for CVD in a large
random sample of the general population; and (b) that the
association of CRP with prevalent CVD in this sample is
greatly reduced by adjustment for these risk factors. These
findings are consistent with those of Mendall et al (2000),
and with their suggestion that CRP may not play a role in
the pathogenesis of CHD, other than through its association
with haematological variables such as fibrinogen. To date,
there are few data to support the hypothesis that reduction
in circulating CRP levels reduces the risk of CVD. In contrast,
there is increasing evidence that reducing plasma fibrinogen
(e.g. by ancrod; Lowe, 2001) or plasma viscosity (e.g. by
pravastatin; Lowe et al, 2000) reduces cardiovascular risk.
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